Plasma Protein Levels and Very Preterm Birth

NCT ID: NCT02007902

Last Updated: 2018-10-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

125 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary aim of this study is to investigate the relationship between early plasma protein levels and hemodynamics in very preterm infants during postnatal transition. Secondary aims are the following: i) to evaluate maternal and neonatal factors affecting plasma protein level at birth; ii) to evaluate the relationship between plasma protein level and albumin level on the first day of life; iii) to evaluate the association between early hypoproteinemia and neonatal mortality and morbidity in very preterm infants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Very Preterm Infants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Very preterm babies

Observational model: cohort

Evaluation of the relationship plasma protein levels - neonatal hemodynamics

Intervention Type OTHER

* Patient inclusion at birth
* Total plasma protein values measurement on cord blood sample at birth
* Hemodynamic evaluation at 6 hours after birth with colour doppler echocardiography and organ blood flow colour doppler
* Total plasma protein and albumin values measurement on plasma sample at 12 hours after birth
* Blood pressure, heart rate, O2 saturation, capillary refill time, rSO2 \[regional (cerebral and somatic) tissue oxygenation by NIRS - near infrared spectroscopy\] will be monitored over 24 hours after birth.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Evaluation of the relationship plasma protein levels - neonatal hemodynamics

* Patient inclusion at birth
* Total plasma protein values measurement on cord blood sample at birth
* Hemodynamic evaluation at 6 hours after birth with colour doppler echocardiography and organ blood flow colour doppler
* Total plasma protein and albumin values measurement on plasma sample at 12 hours after birth
* Blood pressure, heart rate, O2 saturation, capillary refill time, rSO2 \[regional (cerebral and somatic) tissue oxygenation by NIRS - near infrared spectroscopy\] will be monitored over 24 hours after birth.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Parents written informed consent
* Birth at less than 32 weeks of gestational age
* Birth in a III level delivery facility at Reunion Island

Exclusion Criteria

* Major congenital abnormalities
Minimum Eligible Age

1 Minute

Maximum Eligible Age

1 Hour

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

INSERM CIE1, Dijon, 21000, France

UNKNOWN

Sponsor Role collaborator

Centre Hospitalier Universitaire de la Réunion

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Silvia Iacobelli

Role: PRINCIPAL_INVESTIGATOR

CHU de La Réunion -Site du GHSR

Sylvain Samperiz, MD

Role: PRINCIPAL_INVESTIGATOR

CHU de La Réunion - Hôpital Félix Guyon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hopsitalier Universitaire de La Réunion

Saint-Denis, La Réunion, France

Site Status

Centre Hospitalier de La Réunion

Saint-Pierre, La Réunion, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-A00090-45

Identifier Type: OTHER

Identifier Source: secondary_id

2013/CHU/02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.